Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Retained Earnings (2016 - 2025)

Purple Biotech has reported Retained Earnings over the past 7 years, most recently at -$117.6 million for Q4 2022.

  • Quarterly Retained Earnings fell 22.59% to -$117.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$117.6 million through Dec 2022, down 22.59% year-over-year, with the annual reading at -$117.6 million for FY2022, 22.59% down from the prior year.
  • Retained Earnings was -$117.6 million for Q4 2022 at Purple Biotech, down from -$111.6 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$43.3 million in Q2 2018 and troughed at -$117.6 million in Q4 2022.
  • The 5-year median for Retained Earnings is -$85.9 million (2021), against an average of -$81.1 million.
  • Year-over-year, Retained Earnings fell 6.74% in 2019 and then crashed 67.15% in 2020.
  • A 5-year view of Retained Earnings shows it stood at -$43.7 million in 2018, then decreased by 13.4% to -$49.5 million in 2019, then tumbled by 56.54% to -$77.5 million in 2020, then dropped by 23.71% to -$95.9 million in 2021, then fell by 22.59% to -$117.6 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Retained Earnings are -$117.6 million (Q4 2022), -$111.6 million (Q3 2022), and -$106.7 million (Q2 2022).